

Figure W1. Exposure to aspirin or celecoxib decreases cell proliferation of MIP101 and MIP/5-FU cells. (A) The effect of aspirin (■ = 0 mM, □ = 1.8 mM, and ▨ = 3.6 mM aspirin) or (B) celecoxib (■ = 0 μM, □ = 25 μM, and ▨ = 50 μM celecoxib) on cell doubling time of MIP101 and MIP/5-FU cells was calculated based on daily cell counts for three consecutive days ($n = 3$ independent experiments, $*P < .05$).




Figure W2. Cell cycle analysis of MIP101, MIP/5-FU, and MIP/CPT cells after treatment with 1.8 mM aspirin or 50 μM celecoxib for 14 hours and collected after a double thymidine block at various time points, $t = 0, 3, 6, 9, 12,$ and 15 hours (■ = G1 phase, □ = S phase, ▨ = G2 phase).




Figure W3. (A) COX-2 expression in human CRCs. (B) COX-2 expression in relation to disease recurrence. (C) COX-2 expression in relation to stage of disease and survival.